Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05683535 · ClinicalTrials.gov registry record
Adverse Events Related to Low Dose Atropine
A clinical trial of Myopia, Progressive, sponsored by Scripps Health.
- Completed
- Registry status
- 148
- Enrollment target
- 1
- Study location
NCT05683535: Completed study of Myopia, Progressive, sponsored by Scripps Health.
NCT05683535 is a study of Myopia, Progressive that has completed, run by Scripps Health. The registered enrollment target is 148 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05683535, a study of Myopia, Progressive, has completed, sponsored by Scripps Health.
- COMPLETED
- Registry status
- 148 participants
- Enrollment target
- 1
- Study location
Study Summary
Progressive myopia can lead to severe vision loss and is associated with retinal detachment, glaucoma, and other comorbidities. Several studies have shown that off-label, low-dose atropine eye drops slow the progression of myopia. Many eye care providers are now prescribing off-label atropine eye drops for their myopic patients, with the prescribed concentrations varying amongst providers. The purpose of this study is to determine if low-dose atropine eyedrops used daily, cause adverse effects to the eyes. Patients currently using 0.01%, 0.03%, or 0.05% atropine eye drops obtained from compounding pharmacies will be assessed for associated adverse effects.
Primary Outcome
Summary of total adverse events and severity of adverse events, by dose level at time of the adverse event
Conditions Studied
Interventions
- DRUG Atropine Sulfate
Study Locations (1)
California
- Laura Kirkeby - San Diego
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2018-06-19 |
| Est. Completion | 2023-01-09 |
What the finished NCT05683535 record still lists
NCT05683535 is an observational study that tracks outcomes without assigning an intervention. The registered 148 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Myopia, Progressive appearing as the primary indexed condition, and to 1 intervention - of which Atropine Sulfate is the first listed.
NCT05683535 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT05683535 about?
NCT05683535 is a clinical study titled "Adverse Events Related to Low Dose Atropine". Progressive myopia can lead to severe vision loss and is associated with retinal detachment, glaucoma, and other comorbidities. Several studies have shown that off-label, low-dose atropine eye drops slow the progression of myopia. Many eye care providers are now prescribing off-label atropine eye dr...
What is the current status of trial NCT05683535?
This trial is currently completed. The enrollment target is 148 participants. The study started on 2018-06-19. Estimated completion is 2023-01-09.
What conditions does trial NCT05683535 study?
This clinical trial studies the following conditions: Myopia, Progressive.
What interventions are being tested in trial NCT05683535?
The interventions under investigation include: Atropine Sulfate (DRUG).
Who is sponsoring clinical trial NCT05683535?
This trial is sponsored by Scripps Health, which has 30 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05683535 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia, Progressive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00739362 · 148 participants · Phase 2
Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
- NCT03161223 · 148 participants · Phase 1
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
- NCT03858231 · 148 participants · Phase 4
Opioids Versus Non-Opioids Postoperative After Knee Arthroscopic Surgery
- NCT04486352 · 148 participants · Phase 1
A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI